Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2010

View Archived Issues

DC-based TaReNef AIDS vaccine is safe and immunogenic in phase I/II trial

Pfizer's antibacterial MC-1 shows promising preclinical activity

Snapshots: Recent data on the antibacterial activity of CXA-101

First-in-human data disclosed on NIBR-6465

Pfizer introduces new candidates for inhalation therapy of COPD

Sigma-Tau describes new adenosine A2A receptor antagonists

Prosidion discloses new GPR119 receptor agonists

Phase I/II trials suggest efficacy of Neuvax vaccine in prevention of breast cancer recurrence

Auxilium begins phase III Xiaflex studies in Peyronie's disease

FDA sets date for end-of-phase II meeting on NTx-265

State University of New York, Albany claims novel antiestrogens

Exelixis and Bristol-Myers Squibb collaborate on multiple small-molecule programs

CureVac presents phase I/IIa data on CV-9103 in prostate cancer

GSK describes new tyrosine-protein kinase ITK/TSK inhibitors

Jazz Pharma receives FDA complete response letter regarding JZP-6 for fibromyalgia

FDA approves delayed-release risedronate sodium for postmenopausal osteoporosis

Researchers synthesize new oncolytic gold complexes

Novartis to use ImmunoGen's TAP technology to develop anticancer therapeutics

Seattle Genetics reports phase II data on brentuximab vedotin in lymphoma

ArQule and Daiichi Sankyo agree with FDA on SPA for phase III ARQ-197 trial

Novo Nordisk tenders all of its shares in ZymoGenetics to Bristol-Myers Squibb

FDA approves Vivitrol for prevention of relapse to opioid dependence

Phase III Multikine trial in head and neck cancer approved in Taiwan

Jubilant Organosys becomes Jubilant Life Sciences

Lundbeck acquires exclusive commercial rights to Sycrest outside U.S., China and Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...